drugset / Trial / NCT05386823
Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
HF1K16 is an investigational pegylated liposome formulation of tretinoin for injection for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs). This phase 1 Trial is a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HF1K16.
Timeline
- Start
- 2021-03-20
- Primary completion
- 2021-07-30
- Completion
- 2021-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tretinoin | Small molecule | 3 mg/m2 | Intravenous |
| Subject | Tretinoin | Small molecule | 6 mg/m2 | Intravenous |
Indications
No indication recorded.